Managing Hypertension in Elderly Patients with Orthostatic Hypotension

Understanding the Core Problem

The European Society of Cardiology guidelines acknowledge that symptomatic orthostatic hypotension is a specific exception to their usual recommendation for dual combination therapy as initial treatment 1
The American College of Cardiology and American Heart Association guidelines explicitly warn that caution is advised in initiating antihypertensive pharmacotherapy with 2 drugs in older patients because hypotension or orthostatic hypotension may develop; blood pressure should be carefully monitored 3

Discontinue losartan permanently if it consistently causes symptomatic hypotension despite dose reduction attempts 1
Initiate chlorthalidone 12.5 mg daily or indapamide 1.25 mg daily as the second antihypertensive agent 2
Thiazide-like diuretics are preferred over hydrochlorothiazide due to longer duration of action and superior cardiovascular outcomes evidence 2, 4
This combination (CCB + diuretic) avoids RAS blockade while still providing guideline-concordant dual therapy 1

Add a beta-blocker (e.g., metoprolol succinate 25-50 mg daily) if no contraindications exist 1, 4
The combination of CCB + diuretic + beta-blocker provides three complementary mechanisms without RAS blockade 4

Add spironolactone 12.5-25 mg daily as the preferred fourth-line agent 2, 5
Monitor potassium closely (risk of hyperkalemia even without concurrent RAS blocker) 5

Target systolic BP 130-139 mmHg given the orthostatic hypotension and elderly status 1, 2
The 2024 ESC guidelines recommend 120-129 mmHg if well tolerated, but explicitly state to use the "as low as reasonably achievable" (ALARA) principle when treatment is poorly tolerated 1

Do not combine two RAS blockers (ACE inhibitor + ARB) if you later attempt to reintroduce one—this increases adverse events without benefit 1, 4
Do not escalate amlodipine dose further (already at maximum 10 mg)—adding a different mechanism is more effective than increasing the same drug class 4